Type 1 Diabetes Trial, Recruiting NCT06618612 Sponsor: Organogenesis Condition: Type 1 Diabetes
Back to Type 1 Diabetes

Type 1 Diabetes Trial, Recruiting

NCT06618612
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older.
  • You have been diagnosed with type 1 or type 2 diabetes.
  • Your wound (ulcer) measures at least 1.0 cm² in size at the time of joining.
  • Your wound has been present for at least 4 weeks.
  • Your wound is on your foot, with most of it located below the ankle bone.
  • Your wound is classified as Wagner grade 1 or 2, meaning it is not too deep (confirm with trial site).
  • Blood flow to the affected leg and foot has been checked and confirmed to be adequate.
  • If you have more than one wound, they must be at least 2 cm apart from each other.
  • If your wound is on the bottom of your foot, you must have been using a pressure-relieving method (such as a special boot or cast) for at least 14 days before joining.
  • You agree to use the pressure-relieving method recommended by the study team for the entire duration of the trial.
  • You agree to attend weekly check-up visits as required by the study.
  • You are willing and able to read and sign a consent form to participate.

Who may not be able to join:

  • Your life expectancy is estimated to be less than 6 months.
  • Your wound is not caused by diabetes.
  • Your wound is currently infected, or the skin around it is infected (cellulitis).
  • Your wound is so deep that it exposes a tendon or bone.
  • There are signs of bone infection (osteomyelitis) in or around the wound.
  • You have an infection in the wound or elsewhere in your body that requires antibiotic tablets or injections.
  • You are taking medications that suppress your immune system or chemotherapy drugs that may slow wound healing.
  • You are currently taking a medication called hydroxyurea.
  • You have applied steroid creams directly to the wound within the past month.
  • You have had a partial amputation on the affected foot that makes it difficult to properly relieve pressure on the wound.
  • Your HbA1c (a blood test measuring average blood sugar levels) result from the past 3 months does not meet the study's requirements (confirm with trial site).
  • You have an active or inactive Charcot foot condition that makes it difficult to properly relieve pressure on the wound.
  • You are pregnant or planning to become pregnant within the next 6 months.
  • You have end-stage kidney disease and require dialysis.
  • You have taken part in another clinical trial using an experimental treatment within the past 30 days.
  • In the opinion of the study doctor, you have a medical or psychological condition that could affect how well the study can be carried out.
  • You have received hyperbaric oxygen therapy or a special wound-healing skin product within the 30 days before your first screening visit.
  • Your nutritional assessment score falls below a certain level, indicating significant malnutrition (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Maribel Henao, Organogenesis

Phone: (781) 575-0775

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Organogenesis
Registry
ClinicalTrials.gov
Start date
19 August 2024
Est. completion
19 August 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Determine the efficacy of multiple Polyhexamethylene Biguanide Antimicrobial (PCMPs) plus SOC versus SOC alone in achieving complete closure

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov